Metabolism and Sleep Apnea Treatment
University of Miami · with National Heart, Lung, and Blood Institute (NHLBI) · NCT05539716
Opens the official ClinicalTrials.gov record, with the study team’s contacts. Bored Studies doesn’t enroll anyone.
Key facts
- Compensation
- Not posted. Ask the study team before screening.
- Who can join
- Ages 18–70 · All sexes
- Healthy volunteers
- Accepted
- Study type
- Interventional · Not applicable
- Target enrollment
- 100
- US sites recruiting
- 1
- Study start
- May 20, 2022
- Record last updated
- March 23, 2026
Status re-checked against ClinicalTrials.gov within the last 12 hours.
What the study is about
The purpose of this research study is to see if obstructive sleep apnea (OSA) is associated with abnormalities in fat metabolism. Through this research study, the Investigator will evaluate how fat is metabolized in people with and without sleep apnea, what substances the fat tissue releases, and how these substances might change the way the body uses energy and sugar.
Being studied: PAP Therapy; Lifestyle Counseling Intervention
Conditions: Obstructive Sleep Apnea; Fat Disorder
Eligibility criteria
Copied from the official record. The study team makes the final decision at screening.
Show full criteria
Aim 1 Group:
Inclusion criteria
- Age between 18-70 years
- Ability to provide consent
Exclusion criteria
- Body Mass Index (BMI) > 40 kg/m2
- Prevalent myocardial infarction, coronary revascularization, heart failure, and stroke
- Type 1 or Type 2 diabetes mellitus
- Current or prior use of PAP or oral appliance therapy for OSA
- Use of oral corticosteroids
- Unstable medical conditions that may preclude enrollment in the protocol such as: uncontrolled angina and/or congestive heart failure, uncontrolled blood pressure or resistant hypertension, severe chronic obstructive pulmonary disease, cancer, and active psychiatric disease (e.g., major depression)
- Other sleep disorders (e.g., circadian rhythm disorder, self-reported habitual sleep duration \< 6h)
- Use of supplemental oxygen during wakefulness or sleep
- Central sleep apnea, obesity hypoventilation syndrome or Cheyne-Stokes respiration based on the home sleep test
- Resting awake Oxygen Saturation (SpO2) \< 90%
Aim 2 Group:
Inclusion criteria
- Age between 18-70 years
- Ability to provide consent
- Moderate-to-severe OSA (AHI ≥ 15/h);
- Demonstration of Positive Airway Pressure (PAP) use of > 4 h/night on 70% of the nights during 1-week run-in period
- Successful completion of all of the procedures for Aim 1.
Exclusion criteria
- BMI: ≥ 40 kg/m2
- Type 1 or Type 2 diabetes mellitus
- Current use of PAP or oral appliance therapy for OSA
- Commercial driver or report of motor vehicle accident or near-miss due to sleepiness within the 2 previous years
- Epworth sleepiness score of 18 or more
- Use of oral corticosteroids
- Participation in another clinical trial
- Unstable medical conditions that may preclude enrollment in the protocol such as: uncontrolled angina and/or congestive heart failure, uncontrolled blood pressure or resistant hypertension, severe chronic obstructive pulmonary disease, cancer, and active psychiatric disease (e.g., major depression)
- Other sleep disorders (e.g., circadian rhythm disorder, self-reported habitual sleep duration \< 6h)
- Use of supplemental oxygen during wakefulness or sleep
- Central sleep apnea, obesity hypoventilation syndrome or Cheyne-Stokes respiration based on the home sleep test
- Resting awake SpO2 \< 90%
Recruiting US locations
University of Miami
Miami, FL 33143
Site contact: Naresh Punjabi, MD · 305-243-3963 · npunjabi@miami.edu
Study contacts (from the official record)
- Naresh Punjabi, MD · 305-243-3963 · npunjabi@miami.edu
Similar studies in Florida
All sleep studies in Florida →- RecruitingPhase 3
Clinical Assessment of Response in the Treatment of Depression With Daytime Sleepiness Using Solriamfetol
Axsome Therapeutics, Inc.
- Location
- Jacksonville, FL + 35 other US sites
- Eligibility basics
- Ages 18–65
- RecruitingPhase 2
DReAMzz- Dronabinol and Acetazolamide Medication for Sleep Apnea (ZZ). Dose Confirmation Crossover Study for IHL-42X in Subjects With Obstructive Sleep Apnea.
Incannex Healthcare Ltd
- Location
- Brandon, FL + 11 other US sites
- Eligibility basics
- Ages 18–65
- RecruitingPhase 3
A Study to Learn About the Monthly Dosing Study Medicine Called Berobenatide in Adults With Breathing Problems During Sleep and Overweight or Obesity Who Use a Breathing Machine (PAP) (VESPER-OSA 1)
Pfizer
- Location
- Bradenton, FL + 2 other US sites
- Eligibility basics
- Ages 18+
- RecruitingPhase 2/Phase 3
A Long-Term Study of ALKS 2680 in Subjects With Narcolepsy and Idiopathic Hypersomnia
Alkermes, Inc.
- Location
- Brandon, FL + 32 other US sites
- Eligibility basics
- Ages 18–70